Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
Yuw6ZcuNuTUEAPQj